重症过敏性哮喘接受奥玛珠单抗治疗伴发自身免疫性2型多内分泌综合征
2018/01/19
摘要
单克隆抗体是一种具有广泛前景且有效治疗重症和难治性哮喘的方法。尽管该药物被认为安全，但仍有一些少见的并发症。本例患者为45岁女性，重症过敏性哮喘伴自发性荨麻疹，在接受奥玛珠单抗治疗26个月出现自身免疫性多内分泌2型综合征（APS-2）.病人被确诊为原发肾上腺皮质分泌不足（Addison氏病）和亚急性甲状腺炎伴有自身免疫性萎缩性胃炎。根据我们所知，这是第一例应用奥玛珠单抗治疗出现APS-2，但是否两者相关且互为因果并无充分依据。
Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab.
J Asthma. 2018 Jan 4:1-3. doi: 10.1080/02770903.2017.1414239. [Epub ahead of print]
Rams A, et al.
Abstract
Asthma therapy with monoclonal antibodies is a promising and effective approach for those with a severe and refractory type of disease. Although such a targeted therapy is considered to be safe, unusual complications may occur. We present a case of a 45 year-old female patient with severe allergic asthma and chronic spontaneous urticaria, who developed autoimmune polyendocrine syndrome type 2 (APS-2) after 26 months of omalizumab administration. The patient was diagnosed with primary adrenal insufficiency (Addison's disease) and Hashimoto's thyroiditis accompanied by autoimmune atrophic gastritis. According to our knowledge this is the first description of APS-2 that developed in conjunction with omalizumab treatment, although we have no evidence that the observed phenomenon indicated a cause-effect relationship to omalizumab.
单克隆抗体是一种具有广泛前景且有效治疗重症和难治性哮喘的方法。尽管该药物被认为安全，但仍有一些少见的并发症。本例患者为45岁女性，重症过敏性哮喘伴自发性荨麻疹，在接受奥玛珠单抗治疗26个月出现自身免疫性多内分泌2型综合征（APS-2）.病人被确诊为原发肾上腺皮质分泌不足（Addison氏病）和亚急性甲状腺炎伴有自身免疫性萎缩性胃炎。根据我们所知，这是第一例应用奥玛珠单抗治疗出现APS-2，但是否两者相关且互为因果并无充分依据。
（上海交通大学医学院附属瑞金医院呼吸与危重症医学科 周剑平 万欢英 摘译）
（J Asthma. 2018 Jan 4:1-3. doi: 10.1080/02770903.2017.1414239. [Epub ahead of print]）
（J Asthma. 2018 Jan 4:1-3. doi: 10.1080/02770903.2017.1414239. [Epub ahead of print]）
Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab.
J Asthma. 2018 Jan 4:1-3. doi: 10.1080/02770903.2017.1414239. [Epub ahead of print]
Rams A, et al.
Abstract
Asthma therapy with monoclonal antibodies is a promising and effective approach for those with a severe and refractory type of disease. Although such a targeted therapy is considered to be safe, unusual complications may occur. We present a case of a 45 year-old female patient with severe allergic asthma and chronic spontaneous urticaria, who developed autoimmune polyendocrine syndrome type 2 (APS-2) after 26 months of omalizumab administration. The patient was diagnosed with primary adrenal insufficiency (Addison's disease) and Hashimoto's thyroiditis accompanied by autoimmune atrophic gastritis. According to our knowledge this is the first description of APS-2 that developed in conjunction with omalizumab treatment, although we have no evidence that the observed phenomenon indicated a cause-effect relationship to omalizumab.
上一篇：
哮喘是否影响青少年学校表现？来自瑞典人群出生队列研究结果
下一篇：
儿童哮喘应用ICS后青光眼发生率降低：一项队列研究
